Biotech

All Articles

Vaxcyte climbs on 'stunning' 31-valent PCV gain versus Pfizer

.Vaxcyte introduced what analysts called "spectacular" phase 1/2 data for its 31-valent pneumococcal...

Recursion's human brain illness trial reveals little documentation of efficacy

.Recursion has actually stumbled by means of an early exam of its tech-enabled strategy to drug reve...

Acepodia, Pfizer click with each other for chemistry-based cell treatment

.Phone it a situation of good chemistry: Acepodia, a biotech based on Nobel Champion scientific rese...

Praxis epilepsy medication reduces seizures in period 2 hearing

.Praxis Precision Medicines has actually racked up one more midphase succeed in epilepsy this year, ...

Three directors resign as Dyne articles mixed information for DMD prospect

.After escaping a medical grip numerous years back, Dyne Therapeutics has actually revealed brand-ne...

Arrowhead fires off period 3 records in unusual metabolic disease ahead of market clash with Ionis

.Arrowhead Pharmaceuticals has actually presented its own give ahead of a possible face-off along wi...

Pfizer, Valneva present lyme disease shot successful for second enhancer

.Pfizer and also Valneva may possess about two even more years to wait before they produce the initi...

Fierce Biotech Editor-in-Chief Ayla Ellison Speaks Shop with Michelle Benz on the Future of Biotech.

.Let's study a talk with Ayla Ellison, Fierce Biotech Managing Editor and Michelle Benz as they cove...

New records show how Bayer's asundexian failed to avoid movements

.Bayer put on hold the stage 3 test for its own aspect XIa inhibitor asundexian behind time in 2013 ...

Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials

.Sanofi is still set on taking its multiple sclerosis (MS) med tolebrutinib to the FDA, execs have a...